SEARCH

SEARCH BY CITATION

Disclaimer: Supplementary materials have been peer-reviewed but not copyedited.

FilenameFormatSizeDescription
pmic7172-sup-0001-figures1.ppt5588K

Supporting Figure 1. DM43 - Full MS spectra – Strategy 1.

Supporting Figure 2. DM43 – m/z 2,655.11 – MS2 – Strategy 1. (A) Underivatized (B) Derivatized with SPITC.

Supporting Figure 3. DM64 - Full MS spectra – Strategy 1.

Supporting Figure 4. DM64 – m/z 2,691.15 – MS2 – Strategy 1.(A) Underivatized (B) and (C) Derivatized with SPITC.

Supporting Figure 5. DM43 - Full MS spectra – Strategy 2.

Supporting Figure 6. DM64 - Full MS spectra – Strategy 2.

Supporting Figure 7. DM43 – m/z 976.43 – MS2 – Strategy 2. (A) Underivatized (B) Derivatized with SPITC.

Supporting Figure 8. DM64 – m/z 976.41 – MS2 – Strategy 2. (A) Underivatized (B) Derivatized with SPITC.

Supporting Figure 9. DM64 – m/z 2,075.97 – MS2 – Strategy 2. (A) Underivatized (B) Derivatized with SPITC.

Supporting Figure 10. Native DM43/DM64 treated with PNGase. (A) Coomassie blue R-250 staining (B) Periodic acid-Schiff staining.

Supporting Figure 11. Limited proteolysis assay of native or PNGase F-treated proteins with trypsin.

Supporting Figure 12. Limited proteolysis assay of native or PNGase F-treated proteins with jararhagin.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.